Benjamin Hohl Sells 814 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 814 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $24,420.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total value of $34,937.70.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total value of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.33, for a total transaction of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.54, for a total transaction of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $26.68, for a total transaction of $140,070.00.

Enliven Therapeutics Price Performance

ELVN traded up $0.08 during trading on Tuesday, reaching $28.95. 152,952 shares of the stock were exchanged, compared to its average volume of 260,665. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -14.96 and a beta of 1.10. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $30.03. The business’s 50 day moving average price is $24.23 and its two-hundred day moving average price is $22.77.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ELVN. Quest Partners LLC raised its holdings in Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after buying an additional 742 shares during the period. American Century Companies Inc. boosted its holdings in shares of Enliven Therapeutics by 44.7% during the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after buying an additional 8,540 shares during the period. EntryPoint Capital LLC bought a new position in Enliven Therapeutics during the first quarter worth about $167,000. SG Americas Securities LLC acquired a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at $256,000. Finally, Rhumbline Advisers increased its holdings in shares of Enliven Therapeutics by 29.9% during the second quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after buying an additional 11,420 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.